AzTrials
AzTrials

Postoperative Cardiac ComplicationPhase 2CelDilPreCANCT03752931

Celiprolol Versus Ditiazem for the Prevention of Postoperative Cardiac Arrythmias in Thoracic Surgery

A Phase 2 study testing Celiprolol and Diltiazem in people with Postoperative Cardiac Complication, run by Abderrahmane Mami Hospital at 1 site in Tunisia.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Cardiac arrythmias are the most common cardiac complications after thoracic surgery. They are made primarily of postoperative atrial fibrillation (POAF). They are associated with an increased risk of stroke, increased length of hospital stay and cost of care, and increased long-term mortality. Read more about this study

Who is it for?
Ages 18 to 80 years
Conditions the study is for
Postoperative Cardiac Complication
What is being tested?
Celiprolol and Diltiazem
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
1 siteTunisia
Study dates
Dec 2018to Dec 2020
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age ≥ 18 years Sinus rhythm preoperatively.
  • Surgery at high risk of atrial arrhythmia occurring postoperatively:
  • Bi-lobectomy
  • Pneumonectomie

Who cannot join

  • Signs of myocardial ischemia per or post operative.
  • Persistent postoperative hypotension requiring the use of catecholamines.
  • Persistent bradycardia
  • Decompensated cardiac insufficiency.
  • Acute intestinal obstruction.

Trial locations and contacts

1 site in 1 country.

MARZOUK Mahmoud, MD contact

0021620874718

mahmoudmarzouk@hotmail.fr

OUERGHI Sonia, MD contact

ouerghisonia09@gmail.com

Tunisia1 site
  • Hospital Abderrahmane Mami

    Aryanah

    Marzouk Mahmoud, MD, 0021620874718, mahmoudmarzouk@hotmail.Fr

Other trials in Tunisia

About this study

Official title: Prevention of Postoperative Cardiac Arrythmias in Thoracic Surgery : Celiprolol Versus Diltiazem

Cardiac arrythmias are the most common cardiac complications after thoracic surgery. They are made primarily of postoperative atrial fibrillation (POAF).

They are associated with an increased risk of stroke, increased length of hospital stay and cost of care, and increased long-term mortality.

Randomized , single-blind prospective study in the anesthesia and intensive care department of Abderrahmen Mami hospital Ariana Tunisia comparing the efficacy of Diltiazem versus Celiprolol in the prevention of postoperative cardiac arrythmias in patients proposed for pneumonectomy and bilobectomy.

Read the detailed description

Cardiac arrythmias are the most common cardiac complications after thoracic surgery. They are made primarily of postoperative atrial fibrillation (POAF).

They are associated with an increased risk of stroke, increased length of hospital stay and cost of care, and increased long-term mortality.

According to the American Association of Thoracic Surgery (AATS), interventions at high risk for FAPO (> 15%) are: anterior mediastinal mass resection, thoracoscopic lobectomy, thoracotomy lobectomy, pneumonectomy, pleurectomy, tracheal resection, emphysema bubble, bronchopleural fistula repair, lung transplantation and oesophagectomy. And it has been shown that the occurrence of postoperative atrial fibrillation is correlated with the extent of resection in case of lung resection surgery such as lobectomy or pneumonectomy.

Based on their multifactorial etiology, different pharmacological classes have been used for the prevention of POAF with varying degrees of success such as Amiodarone, Digoxin, Flecaine, Magnesium Sulfate, Beta Blockers, Calcium Inhibitors and Statins.

Recommendations were made for the prevention of POAF by the Society of Thoracic Surgeons (STS) in 2011 and the AATS in 2014 and concluded that Diltiazem is recommended for prevention and it is a Grade IIA for recommendations of 2011 and a grade IIB for the 2014 recommendations. Beta-blockers (BB) are recommended and it is a grade IIB for the 2011 recommendations. In addition, amiodarone is not recommended in case of pneumonectomy because of of its pulmonary toxicity for the 2011 recommendations and is ranked grade IIA for the 2014 recommendations.

A meta-analysis published in Chest in 2017 involving 22 studies and 2891 patients showed that the pharmacological prevention of postoperative rhythm disorders after thoracic surgery decreases their incidence but does not reduce mortality in the short term. Several drugs have been studied. Betablockers have the probability of being the most effective agent. Calcium inhibitors are less effective.

In view of these conflicting results and in the absence of a large randomized controlled trial comparing two pharmacologic agents for the prevention of POAF, a certain degree of uncertainty persists regarding the superiority of one agent over another. especially in case of pulmonary resection surgery. Most studies compare drugs versus placebo. Among these drugs Diltiazem and BB are among the most effective and safe.

Randomized , single-blind prospective study in the anesthesia and chest surgery departments of Abderrahmen Mami hospital Ariana Tunisia.

The objective is to compare the efficacy of Celiprolol -Class II of cardioselective anti-arrhythmic B1 with B2 agonist activity with intrinsic sympathomimetic activity- versus Diltiazem -Class IV antiarrhythmic calcium antagonist with direct cardiac effects- in the prevention of cardiac arrhythmias after thoracic surgery such as bilobectomy and pneumonectomy.

Have been included:

  • Age ≥ 18 years
  • Sinus rhythm preoperatively.
  • Surgery at high risk of atrial arrhythmia occurring postoperatively:

Bi-lobectomy Pneumonectomy

Have not been included:

  • history of cardiac arrhythmia.
  • A prior history of atrio-ventricular block with non-paired degrees II or III.
  • Patients on calcium channel blockers or beta-blockers as background therapy.
  • Hypersensitivity to Diltiazem and / or Celiprolol and / or any of the excipients.
  • Renal insufficiency with creatinine clearance <40 ml / min.
  • wolf parkinson white syndrome.
  • Myasthenia gravis.
  • Chronic Obstructive Pulmonary Disease: GOLD III or IV.

Have been excluded :

  • Signs of myocardial ischemia per or post operative.
  • Persistent postoperative hypotension requiring the use of catecholamines.
  • Persistent bradycardia.
  • Decompensated cardiac insufficiency.
  • Acute bowel obstruction.
  • The main criterion of judgment:
  • Incidence of early postoperative atrial fibrillation.
  • Secondary criteria for judgment:
  • The incidence of late arrhythmia (> 14 days) during or after hospitalization during the 30 postoperative days.
  • The incidence of other rhythm disorders.
  • The duration of the arrhythmia in case of occurrence.
  • Length of stay in intensive care unit and hospital.
  • 30-day mortality.
  • Other complications during 14 days postoperative:

Pulmonary: Atelectasis, pneumonitis, ARDS, Cardiovascular: heart failure, heart attack, pulmonary embolism. Neurological: stroke Acute renal failure. • Product Tolerance: Digestive Disorders, Dizziness, Bradycardia, Hypotension, Bronchospasm, Hypoglycemia or Hyperglycemia.

  • Perioperative management:
  • Preoperatively:

All patients are assessed at the pre-anesthetic consultation. All patients are informed about postoperative treatment to reduce the incidence of arrhythmias.

A consent form is signed for this purpose.

  • Inoperative:
  • General anaesthesia:

Induction: Fentanyl, Propofol, Cisatracurium Maintenance: Propofol to push electric syringe, fentanyl and cisatracurium.

  • Perioperative fluid restriction <25ml / kg / 24h with isotonic saline as much as possible.
  • The extent of pericardial resection and mediastinal lymph node dissection are mentioned.
  • Bleeding estimated peroperatively, the need for catecholamines, labile blood products and intraoperative incidents are noted.
  • Postoperative analgesia combines Paracetamol 1g per 6 hours with thoracic epidural analgesia or multimodal analgesia with morphine titration as needed.

Postoperatively:

  • All patients are admitted to intensive care.
  • Close monitoring of hemodynamic, respiratory and neurological parameters.
  • Patients are randomized into 2 groups:

Group 1: receiving 1 tablet per day of celiprolol 200 mg in the morning from the first day after surgery.

Group 2: receiving 1 capsule per day of diltiazem 200 mg in the morning from the first postoperative day.

The target heart rate is between 70 and 80 bpm by titrating the antiarrhythmic agent.

The treatment will be continued for 14 days.

  • electrocardiogram at 6 hours postoperative or if clinical suspicion of arrhythmia or modification to the scope then twice a day.
  • Postoperative blood count.
  • Magnesemia, phosphoremia, calcemia, and blood ionogram at the first postoperative day and correction if abnormalities.
  • X-ray of the postoperative chest and 1 time per day especially for the research of deviation of the mediastinum in case of pneumonectomy.

The occurrence of an arrhythmia will be treated according to the following algorithm:

  • Look for probable cause of bleeding, pulmonary embolism, pneumothorax, pericardial effusion, mediastinal deviation, hypoxia, myocardial ischemia or sepsis.
  • Optimize the volemia.
  • Correct metabolic disorders.
  • Optimize analgesia.
  • If hemodynamically unstable:

Of duration <48 h: external electric shock and advice cardiology. Duration> 48 h: consider anticoagulation, external electrical shock and cardiology.

-It is hemodynamically stable

Duration <48h:

Consider anticoagulation if CHA2DS2 score VASc> 1, amiodarone IV then per os and notice cardiology.

Duration> 48h: consider anticoagulation, IV amiodarone then per os and opinion cardiology.

  • All patients are referred to outpatient cardiology consultations with a rhythmic holter upon discharge.

The occurrence of another postoperative complication will be noted by specifying the date of occurrence in relation to the arrhythmia:

  • Pulmonary: Atelectasis, pneumonitis, ARDS, need for prolonged mechanical ventilation.
  • Cardiovascular: heart failure, myocardial infarction, pulmonary embolism.
  • Neurological: Stroke
  • Acute renal failure.
Being tested
Celiprolol, Diltiazem
Keywords
Pneumonectomy Thoracic surgery Celiprolol Diltiazem

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CeliprololDrug

    receiving 1 tablet per day of Celiprolol 200 mg in the morning from the first postoperative day after pneumonectomy or bi lobecomty for 2 weeks.

  • DiltiazemDrug

    receiving 1 tablet per day of Diltiazem 200 mg in the morning from the first postoperative day after pneumonectomy or bi lobecomty for 2 weeks.

Study groups in NCT03752931
Study groupRoleWhat they receive
CeliprololActive comparatorreceiving 1 tablet per day of celiprolol (Celiprol®) 200 mg in the morning from the first postoperative day after pneumonectomy or bi lobecomty for 2 weeks.
Receives: Drug: Celiprolol
DiltiazemActive comparatorreceiving 1 capsule per day of diltiazem (Monotildiem® LP) 200 mg in the morning from the first postoperative day after pneumonectomy or bi lobectomy for 2 weeks.
Receives: Drug: Diltiazem

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. incidence of early postoperative atrial fibrillation

    Measured: 14 days

Secondary outcomes (1)
  1. incidence of other cardiac arrythmias and other complications

    Measured: 30 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Nov 2018
  2. Study startDec 2018 (estimated)
  3. Primary completionDec 2019 (estimated)
  4. Study completionDec 2020 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Single group
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03752931
Sponsor's protocol ID
MAMICELDIL
Acronym
CelDilPreCA
Status last verified
Nov 2018
First submitted
21 Nov 2018
Last updated
26 Nov 2018
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Zhao BC, Huang TY, Deng QW, Liu WF, Liu J, Deng WT, Liu KX, Li C. Prophylaxis Against Atrial Fibrillation After General Thoracic Surgery: Trial Sequential Analysis and Network Meta-Analysis. Chest. 2017 Jan;151(1):149-159. doi: 10.1016/j.chest.2016.08.1476. Epub 2016 Oct 8.

    PubMed 27729264
  • Fernando HC, Jaklitsch MT, Walsh GL, Tisdale JE, Bridges CD, Mitchell JD, Shrager JB. The Society of Thoracic Surgeons practice guideline on the prophylaxis and management of atrial fibrillation associated with general thoracic surgery: executive summary. Ann Thorac Surg. 2011 Sep;92(3):1144-52. doi: 10.1016/j.athoracsur.2011.06.104. No abstract available.

    PubMed 21871327
  • Frendl G, Sodickson AC, Chung MK, Waldo AL, Gersh BJ, Tisdale JE, Calkins H, Aranki S, Kaneko T, Cassivi S, Smith SC Jr, Darbar D, Wee JO, Waddell TK, Amar D, Adler D; American Association for Thoracic Surgery. 2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures. J Thorac Cardiovasc Surg. 2014 Sep;148(3):e153-93. doi: 10.1016/j.jtcvs.2014.06.036. Epub 2014 Jun 30. No abstract available.

    PubMed 25129609

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Celiprolol and Diltiazem in people with Postoperative Cardiac Complication, run by Abderrahmane Mami Hospital at 1 site in Tunisia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 26 Nov 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Tunisia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact MARZOUK Mahmoud, MD (0021620874718, mahmoudmarzouk@hotmail.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

incidence of early postoperative atrial fibrillation (time frame: 14 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03752931, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Nov 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in